New drug targets for BRCA-driven cancer uncovered

by Brigham and Women's HospitalCredit: CC0 Public DomainBRCA1 and BRCA2 ("BReast CAncer genes") are critical tumor suppressor genes—women carrying a mutation in one of these genes h

Updated on: March 30,2024 16

New drug targets for BRCA-driven cancer uncovered

by Brigham and Women's HospitalCredit: CC0 Public DomainBRCA1 and BRCA2 ("BReast CAncer genes") are critical tumor suppressor genes—women carrying a mutation in one of these genes h

Updated on:March 30,2024 16

ASCO endorses SIO guideline for integrative Tx in breast cancer

(HealthDay)—The American Society for Clinical Oncology (ASCO) has endorsed the Society for Integrative Oncology (SIO) guideline on the use of integrative therapies during and after breast cancer treat

Updated on: March 30,2024 19

ASCO endorses SIO guideline for integrative Tx in breast cancer

(HealthDay)—The American Society for Clinical Oncology (ASCO) has endorsed the Society for Integrative Oncology (SIO) guideline on the use of integrative therapies during and after breast cancer treat

Updated on:March 30,2024 19

Advancing neuropathology with AI-driven classification of diffuse gliomas

by Liu Jia,Chinese Academy of SciencesTen examples of classification results on the external testing sets. Credit:Nature Communications(2023). DOI: 10.1038/s41467-023-41195-9Diffuse

Updated on: March 30,2024 11

Advancing neuropathology with AI-driven classification of diffuse gliomas

by Liu Jia,Chinese Academy of SciencesTen examples of classification results on the external testing sets. Credit:Nature Communications(2023). DOI: 10.1038/s41467-023-41195-9Diffuse

Updated on:March 30,2024 11

ASCO: liquid biopsy accurate for detecting colorectal cancer

(HealthDay)—Liquid biopsy that identifies circulating tumor cells in a blood sample has high accuracy for detecting colorectal cancer (CRC), according to a study presented at the American Society of C

Updated on: March 30,2024 13

ASCO: liquid biopsy accurate for detecting colorectal cancer

(HealthDay)—Liquid biopsy that identifies circulating tumor cells in a blood sample has high accuracy for detecting colorectal cancer (CRC), according to a study presented at the American Society of C

Updated on:March 30,2024 13

App an effective tool to record sun exposure

by Queensland University of TechnologyCredit: Queensland University of TechnologyA smartphone app is an accessible tool that reliably measures the amount of exposure to the sun's skin-damagin

Updated on: March 30,2024 14

App an effective tool to record sun exposure

by Queensland University of TechnologyCredit: Queensland University of TechnologyA smartphone app is an accessible tool that reliably measures the amount of exposure to the sun's skin-damagin

Updated on:March 30,2024 14

BRCA1/2 genetic testing recommendations still leave issues unresolved

by Perelman School of Medicine at the University of PennsylvaniaCredit: CC0 Public DomainThe U.S. Preventive Services Task Force (USPSTF) has released a new Recommendation Statement forBRCA

Updated on: March 30,2024 19

BRCA1/2 genetic testing recommendations still leave issues unresolved

by Perelman School of Medicine at the University of PennsylvaniaCredit: CC0 Public DomainThe U.S. Preventive Services Task Force (USPSTF) has released a new Recommendation Statement forBRCA

Updated on:March 30,2024 19

ASH: A+AVD beats ABVD for advanced Hodgkin's lymphoma

(HealthDay)—For patients with advanced-stage Hodgkin's lymphoma, brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) have superior efficacy to doxorubicin, bleomycin, vinblastin

Updated on: March 30,2024 14

ASH: A+AVD beats ABVD for advanced Hodgkin's lymphoma

(HealthDay)—For patients with advanced-stage Hodgkin's lymphoma, brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) have superior efficacy to doxorubicin, bleomycin, vinblastin

Updated on:March 30,2024 14

ASCO: undertreatment seen for women with head and neck cancer

(HealthDay)—Females with head and neck cancer (HNC) are less likely to receive intensive chemotherapy and radiation, and have an increased relative risk for death from HNC versus other causes, accordi

Updated on: March 30,2024 12

ASCO: undertreatment seen for women with head and neck cancer

(HealthDay)—Females with head and neck cancer (HNC) are less likely to receive intensive chemotherapy and radiation, and have an increased relative risk for death from HNC versus other causes, accordi

Updated on:March 30,2024 12

ASCO: low-dose chemo benefits advanced gastroesophageal cancer

(HealthDay)—For frail and elderly patients with advanced gastroesophageal cancer (aGOAC), low-dose chemotherapy is noninferior to high-dose chemotherapy for progression-free survival, according to a s

Updated on: March 30,2024 16

ASCO: low-dose chemo benefits advanced gastroesophageal cancer

(HealthDay)—For frail and elderly patients with advanced gastroesophageal cancer (aGOAC), low-dose chemotherapy is noninferior to high-dose chemotherapy for progression-free survival, according to a s

Updated on:March 30,2024 16

An antenna for detecting breast cancer

by David Bradley,InderscienceCredit: CC0 Public DomainBreast cancer is a common illness around the world. It is the most common invasive of cancers in women and affects around one in eight and r

Updated on: March 30,2024 16

An antenna for detecting breast cancer

by David Bradley,InderscienceCredit: CC0 Public DomainBreast cancer is a common illness around the world. It is the most common invasive of cancers in women and affects around one in eight and r

Updated on:March 30,2024 16

ASCT may offer alternative for therapy for high-risk follicular lymphoma

(HealthDay)—Autologous stem cell transplantation (ASCT) may be an effective treatment option in high-risk, early therapy failure (ETF) follicular lymphoma (FL), prior to the use of rituximab, accordin

Updated on: March 30,2024 14

ASCT may offer alternative for therapy for high-risk follicular lymphoma

(HealthDay)—Autologous stem cell transplantation (ASCT) may be an effective treatment option in high-risk, early therapy failure (ETF) follicular lymphoma (FL), prior to the use of rituximab, accordin

Updated on:March 30,2024 14

ASH: A+CHP bests CHOP for peripheral T-cell lymphoma

(HealthDay)—For patients with CD30-positive peripheral T-cell lymphoma, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) is superior to cyclophosphamide, doxorubicin, vincris

Updated on: March 30,2024 19

ASH: A+CHP bests CHOP for peripheral T-cell lymphoma

(HealthDay)—For patients with CD30-positive peripheral T-cell lymphoma, brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone (A+CHP) is superior to cyclophosphamide, doxorubicin, vincris

Updated on:March 30,2024 19